Imahe area here
Image area here

Trial Details

  • 85728 (8b)
  • The study drug will involve a new compound being developed for the treatment of Multiple Sclerosis (MS). MS is the leading cause of neurological disability in young adults and is the most common disorder of the central nervous system.

You may be eligible to apply for this study if:

  • Women who might wish to participate must have been surgically sterilised for at least 6 months, or have been postmenopausal for at least 1 year.
  • Men who might wish to participate must be willing to use a double barrier method of contraception from the start of the study and for three months after completion of the study
  • You must be a non smoker and not have used any nictine containing products in the last 3 months
  • Participants must weigh more than 70kg and have a body mass index (BMI) of 18-30kg/m2

    • You will not be eligible to apply for this study if:

  • You have received a vaccination in the last 2 months
  • You have been a blood donor in the last 2 months
  • You have any current illness
  • You have any acute or chronic infectious disease in your medical history
  • You have a history of fainting
  • You have any heart failure or left ventricular dysfunction in your family
  • You have any allergies to medication
  • You have history of respiratory disease
  • You have a history of any liver or kidney disease
  • You have tested positive for hepatitis B, C or HIV
  • You have a history of alcohol or drug abuse

    • Screening Dates:

    Please call 01895 614888 for the latest screening schedule

    Dates of In-house stay:

    Sunday 3rd August 2008 - Saturday 9th August 08

    Outpatient visit dates:

    Monday 11th August 08 and Thursday 14th August 08

    Follow up visit:

    TBC

    « Back to Trials

    The PAREXEL Clinical Pharmacology Research Unit
    Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ
    VOLUNTEER FREEPHONE - 0800 389 8930 | Email: drugtrial@parexel.com